Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Common Equity history runs 14 years deep, the most recent figure standing at $636.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 5.22% year-over-year to $636.0 million; the TTM figure through Mar 2026 stood at $636.0 million (up 5.22% YoY), while the FY2025 annual figure was $722.2 million, up 7.52% from the prior year.
• Common Equity for Q1 2026 stood at $636.0 million, down from $722.2 million in the prior quarter.
• The five-year high for Common Equity was $722.2 million in Q4 2025, with the low at $141.9 million in Q2 2022.
• The 5-year median for Common Equity is $503.0 million (2025), against an average of $469.2 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 30.67% in 2023, then jumped 149.49% in 2024.
• Viridian Therapeutics, Inc.\DE's Common Equity stood at $395.1 million in 2022, then increased by 11.89% to $442.0 million in 2023, then soared by 51.95% to $671.6 million in 2024, then gained by 7.52% to $722.2 million in 2025, then dropped by 11.93% to $636.0 million in 2026.
• Business Quant data shows VRDN's Common Equity at $636.0 million in Q1 2026, $722.2 million in Q4 2025, and $503.0 million in Q3 2025.